The proposed bill would update current statutes to enhance the role of pharmacists in Arizona by allowing them to independently order, perform, and interpret certain medical tests, as well as initiate treatment for patients aged 12 and older who test positive for specific conditions like influenza and COVID-19. It introduces new requirements for the Arizona State Board of Pharmacy to develop a statewide written protocol that includes documentation, record retention, patient screening, and treatment instructions. Additionally, the bill mandates that pharmacists notify patients' primary care providers after initiating treatment or observing adverse reactions, while also establishing an independent advisory committee to assist in protocol development.

Key updates include provisions that specify treatment initiated by pharmacists does not create liability for primary care providers regarding adverse reactions, and that patients must be informed that testing and treatment are conducted by pharmacists without physician oversight. The advisory committee's composition will change to include two primary care physicians, with at least one focusing on children and adolescents, while a licensed nurse practitioner specializing in primary care will be added. The bill also eliminates the requirement for a physician licensed by the ABOE on the committee, aiming to improve oversight and representation in pharmacist-initiated treatments.

Statutes affected:
Introduced Version: 32-1979.04
Senate Engrossed Version: 32-1979.04